Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Inclusion Criteria: Histologically or cytologically confirmed non-small cell lung cancer Mixed tumors allowed unless small cell elements are present Stage IIIB or IV or recurrent disease At least 1 measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan No known brain metastases Performance status - ECOG 0-1 More than 3 months Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 2 mg/dL AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver involvement present) Creatinine ≤ 2 mg/dL Creatinine clearance ≥ 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No peripheral neuropathy > grade 1 No other concurrent uncontrolled illness No ongoing or active infection No psychiatric illness or social situation that would preclude study participation No more than 1 prior chemotherapy regimen Two prior chemotherapy regimens allowed provided 1 of the 2 regimens was gefitinib monotherapy as second-line therapy At least 4 weeks since prior chemotherapy (6 weeks for carmustine, mitomycin, or nitrosoureas) and recovered At least 4 weeks since prior radiotherapy (except localized radiotherapy for symptom relief) and recovered Prior bortezomib allowed provided patient achieved at least a partial response (of at least 6 months duration), received no other therapy since the last dose of bortezomib, and has no residual toxicity greater than grade 1 No other concurrent investigational or commercial agents or therapies for malignancy